CD24 and S100A4 Expression in Resectable Pancreatic Cancers With Earlier Disease Recurrence and Poor Survival

Lee, Sang Hyub; Kim, Haeryoung; Hwang, Jin-Hyeok; Shin, Eun Hee; Lee, Hye Seung; Hwang, Dae Wook; Cho, Jai Young; Yoon, Yoo Seok; Han, Ho‐Seong; Hyo, Byung

doi:10.1097/mpa.0000000000000097

Cited by 33 publications

(24 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A meta-analysis by Li et al which analyzed the relation of CD133 expression and survival in PDAC performed on the group of 908 patients showed shorter survival of individuals with high expression of CD133 comparing to those with low expression of this biomarker [37]. Similarly, high expression of CD24 in PDAC correlated with poor prognosis in the study of Lee et al performed on the group of 67 PDAC with resected tumor [38]. Additionally, an analysis on 96 PDAC patients by Hou et al showed shorter survival in individuals who presented coexpression of CD44 and CD133 [39].…”

Section: Discussionmentioning

confidence: 99%

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis

et al. 2017

View full text Add to dashboard Cite

Cancer stem cells (CSC) play an important role in pancreatic carcinogenesis and prognosis. The study aimed at examining the expression of CD24, CD44, and CD133 in human PDAC and CP in order to evaluate its clinicopathological correlations and the clinical significance. Surgical specimens from 23 patients with PDAC and 15 patients with chronic pancreatitis after pancreatic resection were stained with CD24, CD44, and CD133 antibodies. The intensity of staining was scored from 0 (negative) to 3 (strongly positive). Results. Mean CD24 staining score in PDAC was 1.38 ± 0.76 and was significantly higher than that in CP: 0.70 ± 0.53 (p < 0.01); CD44 score in PDAC was 2.23 ± 0.42 and was significantly higher than that in CP: 1.87 ± 0.55 (p < 0.05); CD133 score 0.93 ± 0.58 was not different from CP: 0.71 ± 0.43 (p > 0.05). CD44 immunoreactivity was significantly higher (p < 0.05) in pT1 and pT2 patients together as regards pT3: 2.45 ± 0.37 versus 2.06 ± 0.38 as well as in N0 patients compared to N1 patients: 2.5 ± 0.38 versus 2.04 ± 0.34. Conclusions. CD24 and CD44 are upregulated in human pancreatic cancer compared to chronic pancreatitis. CD44 immunoreactivity decreases with the tumor advancement and may represent the negative PDAC prognostic factor. Each CSC marker was differently related to PDAC advancement. CD133 may lack clinical significance in PDAC.

show abstract

Section: Discussionmentioning

confidence: 99%

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis

et al. 2017

View full text Add to dashboard Cite

show abstract

“…Loss of E-cadherin has been reported to exert an unfavorable impact on the overall survival rate of CRC patients (8). However, N-cadherin, a transmembrane protein similar to E-cadherin, has been reported to be abnormally expressed in multiple tumors, including pancreatic (9), gastric (10) and hepatocellular (11) cancers. High expression of N-cadherin predicts poor outcome in patients with superficial urothelial carcinoma and gallbladder cancer (12,13).…”

Section: Introductionmentioning

confidence: 99%

N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer

Yan

Liu

et al. 2015

Molecular Medicine Reports

View full text Add to dashboard Cite

Recent studies have indicated that the epithelial-mesenchymal transition (EMT) is a key molecular mechanism involved in the development of colorectal cancer (CRC). N-cadherin is a mesenchymal marker of the EMT and has been closely linked to several human malignancies. However, its role in CRC has remained elusive. In the present study, qRT-PCR and western blot analysis indicated that N-cadherin expression was higher in tumor tissues than in that in their adjacent normal tissues. Immunohistochemical evaluation of N-cadherin and E-cadherin (an epithelial marker of the EMT), indicated that N-cadherin expression was significantly associated with tumor differentiation, tumor size as well as tumor, nodes and metastasis stage. Correlation analysis suggested the expression of N-cadherin was negatively correlated with that of E-cadherin in CRC tissues. Kaplan-Meier analysis indicated that patients with high N-cadherin expression had a significantly lower overall survival and disease-free survival rate than those with low N-cadherin expression, while the opposite was found for E-cadherin. Of note, the present study found that high N-cadherin expression was an independent prognostic factor for CRC. In vitro assays showed that N-cadherin was widely expressed in CRC cell lines and silencing of N-cadherin suppressed the proliferation and migration of the CRC cell line HT-29 by upregulating E-cadherin, suggesting a potential role of N-cadherin in inducing EMT. In conclusion, the present study suggested that N-cadherin has the potential of serving as a novel prognostic predictor and a promising therapeutic target for CRC.

show abstract

“…In addition, S100A4 expression in pancre- atic cancers was significantly associated with earlier tumor recurrence. (20) Although statistical significance was not reached in this study (possibly due to the small number of cases studied), E-cadherin expression loss and S100A4 protein expression were more frequently seen in PanIN-3 lesions associated with CP compared to those without a CP background, supporting the notion that chronic inflammation may contribute to EMT and offering potential clinical target for prevention of metastasis by inhibition of EMT.…”

Section: Discussionmentioning

confidence: 50%

Presence of pancreatic intraepithelial neoplasia‐3 in a background of chronic pancreatitis in pancreatic cancer patients

et al. 2015

Self Cite

View full text Add to dashboard Cite

The clinical significance of pancreatic intraepithelial neoplasia (PanIN) lesions in non-neoplastic pancreata of pancreatic ductal adenocarcinoma (PDAC) patients remains controversial. As chronic inflammation has been recently demonstrated to promote dissemination of in situ precancerous lesions, we investigated the prognostic significance of PanINs associated with chronic pancreatitis (CP) in PDAC patients. This retrospective study analyzed 125 curatively resected PDAC specimens for the presence of PanIN and CP. Univariate and multivariate analyses were performed to identify significant predictive factors for poor disease-free survival (DFS) and overall survival (OS). Immunohistochemical staining for E-cadherin and S100A4, markers of epithelial-mesenchymal transition, was performed on resected specimens containing PanIN-3 lesions. CP was observed in 27.2% (34/125) and PanIN-3 in 25.6% (32/125) of specimens. In the presence of CP, PanIN-3 was significantly associated with decreased survival (DFS: 4.3 vs 15.5 months, P = 0.021; OS: 16.3 vs 30.9 months, P = 0.004). PanIN-3 was not a prognostic factor in the absence of CP. The presence of both PanIN-3 and CP was associated with a reduced survival compared to the other cases, in both univariate (DFS: P = 0.039; OS: P = 0.023) and multivariate (DFS: P = 0.020; OS: P = 0.076) analyses. Furthermore, E-cadherin loss and S100A4 expression were more frequently observed in PanIN-3 lesions of CP specimens than in those of non-CP specimens, although not statistically significant. PanIN-3 in association with CP is a significant prognostic factor for decreased survival in PDAC patients, suggesting that chronic inflammation may accelerate the progression of preinvasive high-grade PanIN.

show abstract

CD24 and S100A4 Expression in Resectable Pancreatic Cancers With Earlier Disease Recurrence and Poor Survival

Cited by 33 publications

References 35 publications

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis

Expression and Clinical Significance of Cancer Stem Cell Markers CD24, CD44, and CD133 in Pancreatic Ductal Adenocarcinoma and Chronic Pancreatitis

N-cadherin, a novel prognostic biomarker, drives malignant progression of colorectal cancer

Presence of pancreatic intraepithelial neoplasia‐3 in a background of chronic pancreatitis in pancreatic cancer patients

Contact Info

Product

Resources

About